无创检测预测代偿期进展性慢性肝病失代偿的多中心研究
结果显示NITs与肝静脉压力梯度(HVPG)对失代偿的预测能力相似,白蛋白是重要预测因子,结合白蛋白的模型可区分1年失代偿风险极低(1.4-2.1%)与约15%的高危患者。
要点
- NITs预测CSPH对失代偿的预后价值与HVPG相当
- 白蛋白是仅次于HVPG或NITs的失代偿预测因子
- 结合白蛋白的模型可识别1年失代偿风险极低(<2%)的患者
核心结论
- 在当代欧洲cACLD患者中,无创估计的CSPH风险对失代偿的预测能力与HVPG相当。
- 包含门脉高压指标和白蛋白的模型可区分失代偿风险极低与1年风险约15%的患者。
研究设计与样本
- 随访至发生肝失代偿、肝细胞癌、死亡或末次访视。
主要发现
- 队列中MASLD占40.7%,MetALD/ALD占32.1%,病毒性占16.2%,CSPH患病率为62.0%。
- 1年及2年累积失代偿发生率分别为7.3%(95% CI 5.9-8.7%)和12.6%(10.3-14.9%)。
- 白蛋白是失代偿的关键预测因子(sHR 0.836;95% CI 0.779-0.897)。
- HVPG(白蛋白校正后sHR 1.126;95% CI 1.059-1.198)、NICER(白蛋白校正后sHR 1.207;95% CI 1.043-1.397)和ANTICIPATE±NASH(白蛋白校正后sHR 1.174;95% CI 1.003-1.374)均与失代偿独立相关。
- 包含白蛋白与HVPG或CSPH-NIT的模型对失代偿具有高C-index(0.772-0.806)。
关键数值与推荐
- 以预测1年无失代偿生存概率≥95%或<95%分层,约60%患者1年风险极低(1.4-2.1%),其余患者1年失代偿风险为14.3-16.0%。
临床怎么用
- 无创检测可用于cACLD患者CSPH风险评估和失代偿风险分层。
- 结合白蛋白与门脉高压指标的无创模型有助于识别可从预防性策略中获益的高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The NICER (liver and spleen stiffness by vibration-controlled transient elastography, platelet count, and BMI) and the ANTICIPATE±NASH models predict clinically significant portal hypertension (CSPH) in compensated advanced chronic liver disease (cACLD). This study reports follow-up data from the NICER cohort, comparing the prognostic utility of non-invasive tests for CSPH (CSPH-NITs) and hepatic venous pressure gradient (HVPG). METHODS: Patients with Child-Turcotte-Pugh A cACLD (liver stiffness ≥10 kPa and/or F3/4) from 16 European centres undergoing paired HVPG and CSPH-NIT assessment between 2020-2023 were included and followed until incident hepatic decompensation, hepatocellular carcinoma, death, or last visit. RESULTS: Three hundred and fifty-eight patients with cACLD were included (MASLD: 40.7%; MetALD/ALD: 32.1%; viral: 16.2%), with a CSPH prevalence of 62.0%. The cumulative 1-year and 2-year incidences of decompensation were 7.3 (95% CI 5.9-8.7%) and 12.6 (10.3-14.9%). Albumin levels were a key predictor of decompensation (subdistribution hazard ratio [sHR] 0.836; 95% CI 0.779-0.897), alongside HVPG (albumin-adjusted SHR 1.126; 95% CI 1.059-1.198), NICER (albumin-adjusted SHR 1.207; 95% CI 1.043-1.397), or ANTICIPATE±NASH (albumin-adjusted SHR 1.174; 95% CI 1.003-1.374). Models incorporating albumin alongside HVPG or CSPH-NIT achieved high C-indices for decompensation (0.772-0.806). Stratifying patients by a predicted 1-year decompensation-free survival probability of ≥95% or <95% identified approximately 60% of patients as being at negligible 1-year risk (1.4-2.1%), while the remaining patients were at high risk of decompensation (14.3-16.0%). CONCLUSION: In our multicentre study of contemporary European patients with cACLD, non-invasively estimated CSPH risk was as predictive for decompensation as HVPG. Models comprising indicators of portal hypertension and albumin discriminated between patients at negligible decompensation risk and those with a 1-year risk of approximately 15%, i.e. the potential target population for preventive strategies. IMPACT AND IMPLICATIONS: Non-invasive tests (NITs) facilitate the early diagnosis and management of clinically significant portal hypertension in patients with compensated advanced chronic liver disease (cACLD). In our contemporary cohort of patients with cACLD, mainly steatotic liver disease, recruited at 16 European expert centres, the hepatic venous pressure gradient and NITs were similarly predictive of decompensation within 1 to 2 years of follow-up. Serum albumin levels were identified as the second main predictor of decompensation after hepatic venous pressure gradient or NITs for clinically significant portal hypertension. Novel models were developed that could accurately predict the risk of decompensation, thereby refining point-of-care risk stratification and informing clinical trial design for patients with CTP-A cACLD.
引用
- Jachs M, Thöne P, Odriozola A, et al. Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD. J Hepatol. 2025. PMID: 41192692. doi:10.1016/j.jhep.2025.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。